PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-26.20%
Negative net income growth while AVXL stands at 40.04%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.65%
D&A growth of 3.65% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
-4.67%
Negative yoy SBC while AVXL is 36.88%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-515.11%
Both reduce yoy usage, with AVXL at -229.96%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.40%
Some yoy usage while AVXL is negative at -229.96%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-12704.62%
Both negative yoy, with AVXL at -133.59%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-57.07%
Negative yoy CFO while AVXL is 25.98%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-196.22%
Negative yoy CapEx while AVXL is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-196.22%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Lower share issuance yoy vs. AVXL's 395.42%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
No Data
No Data available this quarter, please select a different quarter.